Griseofulvin: Difference between revisions
Ahmed Zaghw (talk | contribs) No edit summary |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 6: | Line 6: | ||
'''Griseofulvin''' (marketed under the proprietary name '''Grifulvin V''' ]]. It is an [[antifungal drug]] that is administered orally. It is used both in animals and in humans, to treat fungal infections of the skin (commonly known as [[ringworm]]) and nails. It is produced by culture of some strains of the mold ''[[Penicillium]] griseofulvum'', from which it was isolated in 1939.<ref>{{Cite journal | url = http://books.google.com/books?id=XZ2QB7bu5LwC&pg=PA406 | title = Handbook of Preservatives | isbn = 9781890595661 | first1 = Michael | last = Ash | year = 2004}}</ref><ref>http://jama.ama-assn.org/content/172/6/532.full.pdf</ref> | '''Griseofulvin''' (marketed under the proprietary name '''Grifulvin V''' ]]. It is an [[antifungal drug]] that is administered orally. It is used both in animals and in humans, to treat fungal infections of the skin (commonly known as [[ringworm]]) and nails. It is produced by culture of some strains of the mold ''[[Penicillium]] griseofulvum'', from which it was isolated in 1939.<ref>{{Cite journal | url = http://books.google.com/books?id=XZ2QB7bu5LwC&pg=PA406 | title = Handbook of Preservatives | isbn = 9781890595661 | first1 = Michael | last = Ash | year = 2004}}</ref><ref>http://jama.ama-assn.org/content/172/6/532.full.pdf</ref> | ||
==Category== | ==Category== | ||
Antifungal | |||
==US Brand Names== | |||
'''GRIFULVIN V<sup>®</sup>''' | '''GRIFULVIN V<sup>®</sup>''' | ||
==FDA Package Insert== | ==FDA Package Insert== | ||
Revision as of 23:26, 5 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Overview
Griseofulvin (marketed under the proprietary name Grifulvin V ]]. It is an antifungal drug that is administered orally. It is used both in animals and in humans, to treat fungal infections of the skin (commonly known as ringworm) and nails. It is produced by culture of some strains of the mold Penicillium griseofulvum, from which it was isolated in 1939.[1][2]
Category
Antifungal
US Brand Names
GRIFULVIN V®
FDA Package Insert
| Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of Action
The drug binds to tubulin, interfering with microtubule function, thus inhibiting mitosis.
It binds to keratin in keratin precursor cells and makes them resistant to fungal infections. It is only when hair or skin is replaced by the keratin-griseofulvin complex that the drug reaches its site of action. Griseofulvin will then enter the dermatophyte through energy dependent transport processes and bind to fungal microtubules. This alters the processing for mitosis and also underlying information for deposition of fungal cell walls.
References
- ↑ Ash, Michael (2004). "Handbook of Preservatives". ISBN 9781890595661.
- ↑ http://jama.ama-assn.org/content/172/6/532.full.pdf